Spinal Muscular Atrophy Treatment Market by Drug Types in Clinical Pipeline (Phase 3 Drugs – ISIS-SMN Rx 21, Phase 2 Drugs – Olesoxime (TRO19622), LMI070, RO6885247, Phase 1 Drugs – CK-2127107, scAAV9.CB.SMN, RG3039) and Forecast 2017-2021

Spinal Muscular Atrophy Treatment Market by Drug Types in Clinical Pipeline (Phase 3 Drugs – ISIS-SMN Rx 21, Phase 2 Drugs – Olesoxime (TRO19622), LMI070, RO6885247, Phase 1 Drugs – CK-2127107, scAAV9.CB.SMN, RG3039) and Forecast 2017-2021

Spinal muscular atrophy (SMA), also called autosomal recessive proximal spinal muscular atrophy is a genetic disorder that affects the control of muscle movement. It is caused by a loss of specialized nerve cells, called motor neurons, in the spinal cord and the part of the brain that is connected to the spinal cord (the brainstem). SMA is a leading genetic disease causing mortality in infants, as one infant in 6,000 births is estimated to suffer from it. Based on age of onset and symptoms, there are four main types of spinal muscular atrophy: type 1, type 2, type 3, and type 4. Each of these types has a characteristic disease progression and defined mortality rate. Presently, there is no cure for it, and the treatment is targeted towards management of SMA symptoms.

The global spinal muscular atrophy treatment market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).

The global spinal muscular atrophy treatment market segmentation is based on drug types in clinical pipeline (phase 3 drugs – ISIS-SMN Rx 21, phase 2 drugs – Olesoxime (TRO19622), LMI070, RO6885247, phase 1 drugs – CK-2127107, scAAV9.CB.SMN, RG3039). The report also includes qualitative information on the phase 1 and 2 drugs, spinal muscular atrophy prevalence, and treatment pattern followed.

The global spinal muscular atrophy treatment market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global spinal muscular atrophy treatment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global spinal muscular atrophy treatment market and included in this report are AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., and Novartis AG.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Spinal Muscular Atrophy Treatment Market

1. Drugs in Clinical Phase
1.1. Phase 3 Drugs
1.1.1. ISIS-SMN Rx 21
1.2. Phase 2 Drugs
1.2.1. Olesoxime (TRO19622)
1.2.2. LMI070
1.2.3. RO6885247
1.3. Phase 1 Drugs
1.3.1. CK-2127107
1.3.2. scAAV9.CB.SMN
1.3.3. RG3039

2. Geography (Region, Country)
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Middle East
2.6. Rest of the World

3. Company Profiles
3.1. AveXis, Inc.
3.2. Cytokinetics, Inc.
3.3. F.Hoffmann-La Roche Ltd.
3.4. Novartis AG
3.5. Isis Pharmaceuticals, Inc.

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*